S

Dead / Abandoned — Abandoned — no statement of use filed (as of 18 Nov 2024)

What this means for you

This application is over — abandoned 18 Nov 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
97187298
Mark type
Design + words
Filed
23 Dec 2021
Published for opposition
22 Aug 2023
Abandoned
18 Nov 2024
Attorney of record
Christina M. Licursi

Goods and services

  • Class 005 — Pharmaceuticals: Therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene inhibition therapy and/or RNA interference (RNAi), for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene augmentation therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapies using intrathecal administration, for the treatment of genetic diseases and disorders and neurological diseases and disorders; biologic preparations for use in the treatment of genetically based diseases and disorders; biologic preparations for medical purposes, namely, for gene therapy for treating genetic disorders; pharmaceutical preparations that modulate RNA expression for the treatment of neurological diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; gene therapy products, namely, gene delivery pharmaceuticals for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical preparations for gene therapy, gene inhibition and gene augmentation, for the treatment of genetic diseases and disorders and neurological diseases and disorders; viruses, viral vectors and viral constructs, all in the nature of pharmaceutical preparations, for the treatment of neurological diseases and disorders and genetic diseases and disorders; pharmaceutical preparations for gene therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, nucleic acid therapeutics for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, DNA and/or RNA therapeutics for the treatment of genetic disorders and neurological diseases and disorders
  • Class 042 — Scientific and technological services: Development of pharmaceutical preparations for use in gene therapy; genetic engineering and biotechnology research; research and development of new products in the field of gene therapeutics; scientific and medical research in the field of genetics, gene therapy and genetic engineering; laboratory research in the fields of genetics, gene therapy, drug development, biotechnology, microbiology and molecular biology; pharmaceutical drug discovery; scientific research in the field of gene therapy discovery; drug development and therapeutic drug development; genetic drug development and therapeutic drug development; biological research; biological drug development and scientific research in the field of biological development

Owner

Prosecution history

  • 18 Nov 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
  • 18 Nov 2024 — ABANDONMENT - NO USE STATEMENT FILED
  • 12 Apr 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 11 Apr 2024 — SOU EXTENSION 1 GRANTED
  • 11 Apr 2024 — SOU EXTENSION 1 FILED
  • 11 Apr 2024 — SOU TEAS EXTENSION RECEIVED
  • 17 Oct 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 22 Aug 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 22 Aug 2023 — PUBLISHED FOR OPPOSITION
  • 02 Aug 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 19 Jul 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 29 Jun 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 29 Jun 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 29 Jun 2023 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
  • 19 May 2023 — NOTIFICATION OF FINAL REFUSAL EMAILED

View this trademark record on Marksy